HSP90AA1 and gastrointestinal stromal tumor: Recently, the oral Hsp90α/β isoform-specific inhibitor Pimitespib (Tas-116) (Fig. 1) was registered in Japan as the first Hsp90 drug for treating gastrointestinal stromal tumours (TaihoPharmaceutical 2022).